Abstract:The link between tumors and the hemostatic system, first of all platelets, has been acknowledged by numerous studies. Platelets activation at the tumor microenvironment and subsequent intravascular clotting are often associated with cancer complications. Recent clinical studies demonstrated that platelet inhibitors substantially decrease risk of tumor metastasis and mortality in cancer patients, thereby emphasizing clinical importance of platelets. However, the precise function of platelets in cancer progression remains enigmatic. Growing tumors secrete a plethora of growth factors and cytokines (tumor secretome) aiming to change its micro- and macro-environment. These factors promote angiogenesis, induce inflammation, and even stimulate changes in bones prior to metastasis. Tumor secretome signals are likely transmitted through the circulation; however, these signals need to be protected from degradation or utilization prior to reaching their target. Due to their ability to intake and secrete back a wide spectrum of proteins, platelets could function as a mobile storage compartment for the tumor secretome. Using platelet infusion and depletion during tumor growth, we assessed the role of platelets in tumor growth and tumor-induced bone remodeling. We demonstrated that platelet infusion stimulates communications between bone marrow and the tumor, while platelet depletion had the opposite effects. Importantly, tumor-induced changes in bone structure were completely abolished in the absence of platelets. Using platelets from knockout mice with various platelet defects, we demonstrated that platelet secretion (but not aggregation) was crucial for their function in tumor progression. In particular, the function of platelet α-granules is essential for the pro-tumorigenic role of platelets. Analysis of the tumor secretome revealed that 77 percent of tumor-secreted factors are highly enriched within platelets over plasma. Several of these factors are essential mediators of bone remodeling. Thus, our data show that platelet α-granule sequestration and secretion represent a cellular mechanism mediating communication between the bone microenvironment and the primary tumor.

Targeting Erbin-mitochondria axis in platelets/megakaryocytes promotes B cell-mediated antitumor immunity

Targeting Erbin in B cells for therapy of lung metastasis of colorectal cancer

Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation.

Erbin: an important therapeutic target for blocking tumor metastasis

Platelets Promote Breast Cancer Cell MCF-7 Metastasis by Direct Interaction: Surface Integrin Alpha 2 Beta 1-Contacting-mediated Activation of Wnt-beta-catenin Pathway

Role of Erbin in Erbb2-Dependent Breast Tumor Growth

Activated platelets facilitate hematogenous metastasis of breast cancer by modulating the PDGFR-β/COX-2 axis

Platelets and the Tumor Cell Microenvironment

Platelets promote primary hepatocellular carcinoma metastasis through TGF-β1-mediated cancer cell autophagy

Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis

Platelets in the Tumor Microenvironment and Their Biological Effects on Cancer Hallmarks

The Phosphatase PTEN Links Platelets with Immune Regulatory Functions of Mouse T Follicular Helper Cells.

Double-sided Effect of Tumor Microenvironment on Platelets Targeting Nanoparticles.

Exosomal HMGB1 Promoted Cancer Malignancy

Targeting myeloid cells in the tumor sustaining microenvironment

Erbin interacts with c-Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing c-Cbl-mediated ubiquitination and down-regulation of EGFR.

Procoagulant platelets promote immune evasion in triple negative breast cancer

Intratumoral Erythroblastic Islands Restrain Anti-Tumor Immunity in Hepatoblastoma

Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies

Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression

NK Cell Interaction With Platelets and Myeloid Cells in the Tumor Milieu